Navigation Links
Charleston Laboratories, Inc. Announces Senior Global Regulatory Hire
Date:2/15/2017

JUPITER, Fla., Feb. 15, 2017 /PRNewswire/ -- Charleston Laboratories, Inc. announced today that Mark A. Mannebach, Ph.D., R.Ph has joined its team as its Vice President of Global Regulatory Affairs & Quality Assurance.  In his role, Mark will oversee and manage all regulatory submissions and renewals and will be responsible for developing the technical requirements of supply and quality agreements and other external contracts, specifically in relation to Charleston Laboratories' pipeline of products that address unmet needs such as Opioid-Induced Nausea and Vomiting (OINV) and Migraine-Induced Nausea and Vomiting (MINV), including co-promotion activities under its collaboration with Daiichi Sankyo.

"We're proud to add Mark to our already impressive senior leadership team," said Mr. Paul Bosse, President and Chief Executive Officer at Charleston Laboratories.  "Mark's experience in regulatory and quality, coupled with his experience in the pain management industry, will make him a key member of the team."

Mark has more than 30 years of experience in the pharmaceutical industry in a variety of leadership roles at various major pharmaceutical companies including Parke-Davis/Warner-Lambert, Pharmacia, Baxter and Pfizer. For the past 8 years, Mark was the Vice President of Global Regulatory Affairs at Mallinckrodt where he spent a significant amount of his time overseeing the pain management portfolio.  Mark has extensive experience working with the Division of Anesthesia, Analgesia, and Addiction Products (DAAAP) on a number of NDAs including 505(b)(2) applications.  Mark had responsibility for the NDAs for the approved pain products Exalgo, Pennsaid (both 1.5% & 2% topical solutions), Xartemis XR, and Ofirmev.

"I was intrigued by the opportunity that Charleston Laboratories' pipeline and commercial strategy provides me professionally, to continue working in pain management," stated Dr. Mannebach.  "I'm honored to join a team with such deep experience and a commitment to clinical and commercial excellence."

About Charleston Laboratories, Inc.
Charleston Laboratories, Inc. is a privately held, specialty pharmaceutical company focused on the research, development and commercialization of novel pain products to prevent the burdensome side effects related to opioid analgesics and other analgesic products.  In August 2014, the Company entered a strategic collaboration with Daiichi Sankyo for the development and U.S. commercialization of Charleston Laboratories' investigational hydrocodone-based products, including its lead candidate CL-108.

Charleston Laboratories' product pipeline seeks to address unmet needs in Opioid-Induced Nausea and Vomiting (OINV), Postoperative Nausea and Vomiting (PONV), Chemotherapy-Induced Nausea and Vomiting (CINV), Radiation-Induced Nausea and Vomiting (RINV), and Migraine-Induced Nausea and Vomiting (MINV).  Charleston Laboratories intends to introduce novel pain therapies that reduce the burdensome side effects related to opioid analgesics and other products. For more information, please visit www.charlestonlabs.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/charleston-laboratories-inc-announces-senior-global-regulatory-hire-300407320.html


'/>"/>
SOURCE Charleston Laboratories, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Receive Complete Response Letter from FDA for New Drug Application for CL-108 (hydrocodone, acetaminophen, promethazine) Tablets for Oral Use
2. AAIPharma Services Corp. / Cambridge Major Laboratories, Inc. kondigt uitbreiding mogelijkheden en capaciteiten voor steriele productie medicijnen in Charleston, SC aan
3. AAIPharma Services Corp. / Cambridge Major Laboratories, Inc. Announces Expanded Capabilities and Capacity for Sterile Drug Product Manufacturing in Charleston, SC
4. The Business Development Board of Palm Beach Plays Key Role in Charleston Laboratories, Inc. Expansion
5. Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Phase 3 Study of CL-108 Met Primary Endpoints
6. Charleston Area Medical Center Integrates Smart Pump Technology to Advance Patient Safety
7. Charleston Laboratories, Inc. Announces Completion of a Second Phase 3 Clinical Trial on its Lead Product, CL-108, and the Appointment of Dr. Raymond Dionne to its Scientific Advisory Board
8. Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charlestons Second Product, CL-H1T
9. Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Three Poster Presentations at American Pain Society Annual Meeting
10. Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Completion of a Pharmacokinetics Study on CL-108
11. Charleston Laboratories, Inc. Announces Key Clinical Updates for Novel Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... DUBLIN , Mar. 29, 2017 ... "Intraoperative Neuromonitoring (IONM) Market Size & Forecast By Type (Insource ... - 2025" report to their offering. ... The global Intraoperative ... by 2025. The intraoperative neuromonitoring market is anticipated to witness ...
(Date:3/29/2017)... March 29, 2017 Global intravenous (IV) iron and ... by 2021, growing at a CAGR of 5%. ... a doctor to treat anemia or other iron deficiencies. Oral ... the body. However, in some cases, oral administrations are not ... intravenous (IV) iron therapy comes into the picture. ...
(Date:3/29/2017)... 29, 2017 Today, CVS Health officials (NYSE: ... , Department of Public Health Director Gerd Clabaugh ... in announcing the availability of the opioid overdose-reversal medicine ... Iowa.  CVS Health has established a standing order with physicians ... to expand access to the medication in the state.   ...
Breaking Medicine Technology:
(Date:3/30/2017)... Durham, NC (PRWEB) , ... March 30, 2017 ... ... professionals, will host the live audio conference “ Preventing Hospital Readmissions Through Discharge ... April 12, 2017 at 1:00 pm ET. This conference discusses strategies to prevent ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up ... year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic ... focus on finding more effective treatment options, the San Diego Gamma Knife Center ...
(Date:3/29/2017)... ... March 30, 2017 , ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS ... Medical Center will serve as the official title sponsor of the Baltimore Women’s Classic, ... 2017, thousands of women will walk or run the course around the Baltimore Inner ...
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy ... attending prescribers at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. ... recognized as the visionary leader in the training of physicians, scientists, and members ...
(Date:3/29/2017)... ... 29, 2017 , ... Patients interested in receiving quick and ... Jamie Cameron, with or without a referral. The FASTBRACES system is valued for ... each patient’s case, treatment with the FASTBRACES system could be completed in 120 ...
Breaking Medicine News(10 mins):